BRAF and Alzheimer disease: Regarding BRAF targeting, the efficacy of the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) was demonstrated in the randomized, double-blind, phase III COMBI-AD study [4].